Microarrays and biochips are small devices capable of detecting and measuring large numbers of biomarkers simultaneously. Although microarrays have been in research use for over a decade it is only recently that they have moved towards meeting the requirements of the clinical and regulatory communities with the first DNA microarray test being approved by the US FDA in 2007. Further development of microarrays heralds the introduction of faster diagnosis times and will further enable personalized medicine. This report covers future developments in key segments of the microarray market including DNA, protein, tissue and cell microarrays and lab-on-a-chip technologies, providing market forecasts to 2013. In addition the report gives insights into the developmental programs of 45 leading players in this market.
(0 items)
